Previous 10 | Next 10 |
Shares of Fulcrum Therapeutics Inc. (NASDAQ:FULC) traded today at $25.48, eclipsing its 52-week high. This new high was reached on above average trading volume as 12.2 million shares traded hands, while the average 30-day volume is approximately 5.7 million shares. Fulcrum Therapeutics I...
Fulcrum Therapeutics Inc. (NASDAQ:FULC) traded today at a new 52-week high of $20.19. This new high was reached on above average trading volume as 12.2 million shares traded hands, while the average 30-day volume is approximately 205,000 shares. There is potential upside of 15.1% for sha...
CAMBRIDGE, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has priced an underwritten public offering of ...
Fulcrum Therapeutics (NASDAQ: FULC) shares are climbing again after the early clinical-stage biotech announced a plan to raise $100 million in a secondary share offering. Investors aren't thrilled about the share offering, but upgrades from Wall Street analysts helped them get over ...
Gainers: CohBar (NASDAQ:CWBR) +42%, Allied Healthcare Products AHPI +24%, Doximity DOCS +22%, Orphazyme (NASDAQ:ORPH) +13%, Fulcrum Therapeutics FULC +13%. Losers: Biodesix (NASDAQ:BDSX) -19%, Inari Medical (NASDAQ:NARI) -16%, Berkeley Li...
CohBar (NASDAQ:CWBR) +62% on Q2 earnings Good Times Restaurant (NASDAQ:GTIM) +32% on Q3 earnings Upstart Holdings (NASDAQ:UPST) +22% on Q2 earnings Mogo (NASDAQ:MOGO) +20% on Q2 earnings fuboTV (NYSE:FUBO) +16% on Q2 earnings Lantern Pharma (N...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, investors in Fulcrum Therapeutics (NASDAQ: FULC ) are seeing explosive gains. Indeed, shares of this clinical stage biopharma company have skyrocketed. Currently, shares of FULC stock are up around 14...
Fulcrum Therapeutics, Inc. (FULC) Q2 2021 Earnings Conference Call August 10, 2021 08:00 AM ET Company Participants Christi Waarich - Director, IR & Corporate Communications Bryan Stuart - President & CEO Chris Moxham - CSO Chris Morabito - CMO Conference Call Participants Ted Tenthof...
Gainers: Fulcrum Therapeutics (NASDAQ:FULC) +123%. Lightning eMotors (NYSE:ZEV) +52%. 3D Systems (NYSE:DDD) +41%. MediaCo (NASDAQ:MDIA) +40%. Allied Healthcare Products (NASDAQ:AHPI) +27%. Exagen (NASDAQ:XGN) +26%. IMV (NASDAQ:IMV) +23%. Arcturus Therapeutics (NASDAQ:ARCT) +21%. Orphazyme A/S...
Earnings news remained a key theme during Tuesday's midday trading. Squarespace (NYSE:SQSP) and Oak Street Health (NYSE:OSH) both dropped following the release of their quarterly updates. Meanwhile, Turning Point Therapeutics (NASDAQ:TPTX) got a boost after it reported better-than-expected re...
News, Short Squeeze, Breakout and More Instantly...
Fulcrum Therapeutics Inc. Company Name:
FULC Stock Symbol:
NYSE Market:
Fulcrum Therapeutics Inc. Website:
CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...